Quest Diagnostics (DGX) Stock Price, News & Analysis

Company Overview

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers. Through its laboratory network, patient service centers and digital tools, the company supports clinical decision-making, preventive care, wellness programs and occupational health services. It also provides drug testing and other workforce-related testing programs.

The company traces its origins to the clinical laboratory operations of Corning Incorporated and became an independent public company in 1996 before adopting the Quest Diagnostics name. Its operations are primarily based in the United States, with services delivered through facilities and collection locations across the country. Quest Diagnostics is led by Chief Executive Officer Jim Davis.

Key Stats

• Today's Range: $247.39 to $255.61
• 50-Day Range: $226.94 to $252.93
• 52-Week Range: $171.18 to $256.99
• Volume: 590,413 shs
• Average Volume: 979,557 shs
• Market Capitalization: $28.07 billion
• P/E Ratio: 25.47
• Dividend Yield: 1.35%
• Price Target: $248.70
• Consensus Rating: Moderate Buy

Quest Diagnostics Stock Analysis - MarketRank™

Quest Diagnostics scored higher than 81% of companies evaluated by MarketBeat, and ranked 105th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Quest Diagnostics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.31%

Earnings Growth

Earnings for Quest Diagnostics are expected to grow by 5.31% in the coming year, from $11.29 to $11.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quest Diagnostics is 25.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quest Diagnostics is 25.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.44.

Price to Earnings Growth Ratio

Quest Diagnostics has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Quest Diagnostics has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.27% of the float of Quest Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Quest Diagnostics has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quest Diagnostics has recently increased by 4.57%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Quest Diagnostics pays a meaningful dividend of 1.37%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Quest Diagnostics has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Quest Diagnostics is 34.26%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.93% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 0.55

News Sentiment

Quest Diagnostics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for Quest Diagnostics this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.

MarketBeat Follows

3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,232,534.00 in company stock.

Percentage Held by Insiders

0.88% of the stock of Quest Diagnostics is held by insiders.

Percentage Held by Institutions

88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 10/21 Dividend: 10/06/2026
• Ex-Dividend for 10/21 Dividend: 10/06/2026
• Dividend Payable: 10/21/2026
• Last Earnings: 10/22/2026
• Today: 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:DGX
• CIK: 1022079
• Web: www.questdiagnostics.com
• Phone: (973) 520-2700
• Fax: 201-462-4169
• Employees: 57,000
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Quest Diagnostics: $248.70
• High Price Target: $262.00
• Low Price Target: $215.00
• Potential Upside/Downside: -2.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.04
• Trailing P/E Ratio: 25.47
• Forward P/E Ratio: 21.47
• P/E Growth: 2.25
• Net Income: $992 million
• Net Margins: 9.53%
• Pretax Margin: 12.60%
• Return on Equity: 16.21%
• Return on Assets: 7.41%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.70
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: $11.04 billion
• Price / Sales: 2.55
• Cash Flow: $15.45 per share
• Price / Cash Flow: 16.53
• Book Value: $72.26 per share
• Price / Book: 3.53

Miscellaneous

• Outstanding Shares: 110,020,000
• Free Float: 109,051,000
• Market Cap: $28.09 billion
• Optionable: Optionable
• Beta: 0.55